Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed -helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Pompilio, Arianna ^a   Crocetta, Valentina ^a   Scocchi, Marco ^b   Pomponio, Stefano ^a   Di Vincenzo, Valentina ^a   Mardirossian, Mario ^b   Gherardi, Giovanni ^c   Fiscarelli, Ersilia ^d   Dicuonzo, Giordano ^c   Gennaro, Renato ^b   Di Bonaventura, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Antimicrobial peptides; Biofilm; Cystic fibrosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; BMAP 27; BMAP 28; COTRIMOXAZOLE; MACROLIDE; P19(9 B); POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ALPHA HELIX; ANTIBACTERIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIAL VIABILITY; BIOFILM; CYSTIC FIBROSIS; IN VITRO STUDY; LUNG; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PLANKTON; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CATTLE; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84865068580     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-145     Document Type: Article

References (43)

1. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP, JAMA 2010 303 2386 2392 10.1001/jama.2010.791 20551409
2. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL, Pediatr Pulmonol 2002 34 91 100 10.1002/ppul.10127 12112774
3. Challenging and emerging pathogens in cystic fibrosis. de Vrankrijker AM, Wolfs TF, van der Ent CK, Paediatr Respir Rev 2010 11 246 254 10.1016/j.prrv.2010.07.003 21109184
4. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL, Pediatr Pulmonol 2010 45 363 370 20232473
5. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. Millar FA, Simmonds NJ, Hodson ME, J Cyst Fibros 2009 8 386 391 10.1016/j.jcf.2009.08.003 19740710
6. Molecular characterization of virulence determinants of Stenotrophomonas maltophilia strains isolated from patients affected by cystic fibrosis. Di Bonaventura G, Prosseda G, Del Chierico F, Cannavacciuolo S, Cipriani P, Petrucca A, Superti F, Ammendolia MG, Concato C, Fiscarelli E, Casalino M, Piccolomini R, Nicoletti M, Colonna B, Int J Immunopathol Pharmacol 2007 20 529 537 17880766
7. Aminoglycoside antibiotics induce bacterial biofilm formation. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI, Nature 2005 436 1171 1175 10.1038/nature03912 16121184
8. Antibiotics as intermicrobial signaling agents instead of weapons. Linares JF, Gustafsson I, Baquero F, Martinez JL, Proc Natl Acad Sci U S A 2006 103 19484 19489 10.1073/pnas.0608949103 17148599
9. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. Molina A, Del Campo R, Maiz L, Morosini MI, Lamas A, Baquero F, Canton R, J Antimicrob Chemother 2008 62 961 967 10.1093/jac/dkn302 18647744
10. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg E, Nature 2000 407 762 764 10.1038/35037627 11048725
11. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Lai Y, Gallo RL, Trends Immunol 2009 30 131 141 10.1016/j.it.2008.12.003 19217824
12. Mammalian defensins in immunity: more than just microbicidal. Yang D, Biragyn A, Kwak LW, Oppenheim JJ, Trends Immunol 2002 23 291 296 10.1016/S1471-4906(02)02246-9 12072367
13. Cathelicidins, multifunctional peptides of the innate immunity. Zanetti M, J Leukoc Biol 2004 75 39 48 12960280
14. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Hancock RE, Sahl HG, Nat Biotechnol 2006 24 1551 1557 10.1038/nbt1267 17160061
15. Cathelicidin peptides as candidates for a novel class of antimicrobials. Zanetti M, Gennaro R, Skerlavaj B, Tomasinsig L, Circo R, Curr Pharm Des 2002 8 779 793 10.2174/1381612023395457 11945171
16. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, Busetti M, Gennaro R, J Antimicrob Chemother 2006 58 950 959 10.1093/jac/dkl382 17023499
17. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Brogden KA, Nat Rev Microbiol 2005 3 238 250 10.1038/nrmicro1098 15703760
18. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Kapoor R, Wadman MW, Dohm MT, Czyzewski AM, Spormann AM, Barron AE, Antimicrob Agents Chemother 2011 55 3054 3057 10.1128/AAC.01516-10 21422218
19. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G, Peptides 2011 32 1807 1814 10.1016/j.peptides.2011.08.002 21849157
20. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Saiman L, Tabibi S, Starner TD, San Gabriel P, Winokur PL, Jia HP, McCray PB, Tack BF, Antimicrob Agents Chemother 2001 45 2838 2844 10.1128/AAC.45.10.2838-2844.2001 11557478
21. The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains. Thwaite JE, Humphrey S, Fox MA, Savage VL, Laws TR, Ulaeto DO, Titball RW, Atkins HS, J Med Microbiol 2009 58 923 929 10.1099/jmm.0.008128-0 19502364
22. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL, Antimicrob Agents Chemother 1995 39 34 39 10.1128/AAC.39.1.34 7535039
23. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL, Am Rev Respir Dis 1985 132 761 765 3931522
24. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. Palmer KL, Aye LM, Whiteley M, J Bacteriol 2007 189 8079 8087 10.1128/JB.01138-07 17873029
25. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Song Y, Salinas D, Nielson DW, Verkman AS, Am J Physiol Cell Physiol 2006 290 741 C749 16207791
26. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G, J Clin Invest 2002 109 317 325 11827991
27. In vitro and in vivo antimicrobial activity of two alpha-helical cathelicidin peptides and of their synthetic analogs. Benincasa M, Skerlavaj B, Gennaro R, Pellegrini A, Zanetti M, Peptides 2003 24 1723 1731 10.1016/j.peptides.2003.07.025 15019203
28. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M, J Biol Chem 1996 271 28375 28381 10.1074/jbc.271.45.28375 8910461
29. Helix induction in antimicrobial peptides by alginate in biofilms. Chan C, Burrows LL, Deber CM, J Biol Chem 2004 279 38749 38754 10.1074/jbc.M406044200 15247257
30. Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. Pacor S, Giangaspero A, Bacac M, Sava G, Tossi A, J Antimicrob Chemother 2002 50 339 348 10.1093/jac/dkf141 12205058
31. Hoiby N, Pseudomonas in cystic fibrosis: past, present, and future Cystic Fibrosis Trust, London, United Kingdom 1998
32. Bacterial biofilms: a common cause of persistent infections. Costerton JW, Stewart PS, Greenberg EP, Science 1999 284 1318 1322 10.1126/science.284. 5418.1318 10334980
33. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Hell E, Giske CG, Nelson A, Romling U, Marchini G, Lett Appl Microbiol 2010 50 211 215 10.1111/j.1472-765X. 2009.02778.x 20002576
34. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M, Curr Med Chem 2011 18 256 279 10.2174/092986711794088399 21110801
35. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N, Pediatr Pulmonol 2009 44 547 558 10.1002/ppul.21011 19418571
36. Extracellular DNA in biofilms. Montanaro L, Poggi A, Visai L, Ravaioli S, Campoccia D, Speziale P, Arciola CR, Int J Artif Organs 2011 34 824 831 10.5301/ijao.5000051 22094562
37. Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms. Barken KB, Pamp SJ, Yang L, Gjermansen M, Bertrand JJ, Klausen M, Givskov M, Whitchurch CB, Engel JN, Tolker-Nielsen T, Environ Microbiol 2008 10 2331 2343 10.1111/j.1462-2920.2008.01658.x 18485000
38. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Hale JD, Hancock RE, Expert Rev Anti Infect Ther 2007 5 951 959 10.1586/14787210.5.6.951 18039080
39. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility texting; sixteenth informational supplement Clinical and Laboratory Standards Institute, 2010
40. Macrolide resistance genotypes and phenotypes among erythromycin- resistant clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci, Italy. Gherardi G, De Florio L, Lorino G, Fico L, Dicuonzo G, FEMS Immunol Med Microbiol 2009 55 62 67 10.1111/j.1574-695X.2008.00499.x 19076222
41. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. Pompilio A, Pomponio S, Crocetta V, Gherardi G, Verginelli F, Fiscarelli E, Dicuonzo G, Savini V, D'Antonio D, Di Bonaventura G, BMC Microbiol 2011 11 159 10.1186/1471-2180-11-159 21729271
42. A simple ultraviolet spectrophotometric method for the determination of protein. Waddell WJ, J Lab Clin Med 1956 48 311 314 13346201
43. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. Kuipers BJ, Gruppen H, J Agric Food Chem 2007 55 5445 5451 10.1021/jf070337l 17539659